atai Life Sciences (ATAI) announced that it has priced its registered underwritten offering of about 23.73 million common shares, at a price of $5.48 per share. atai has granted the underwriters a 30-day option to purchase up to an additional 3.56 million common shares at the public offering price, less the underwriting discount.
The company expects gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $130 million.
The company intends to use the net proceeds of this offering, together with existing cash, cash equivalents and short-term investments, to advance the clinical development of its product candidates and programs, as well as for working capital and general corporate purposes.
The offering is expected to close on October 20, 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.